A pilot study evaluated anakinra followed by standard chemotherapy in women with HER2-negative metastatic breast cancer and demonstrated a sustained decrease in the expression of multiple genes for Toll-like receptor (TLR) and IL-1β families, while increasing the expression of NK and CD8+ T-cells genes that were associated with tumor lysis.36 The anti-IL-1β neutralizing monoclonal antibody canakinumab is currently being evaluated in combination with various immunotherapy agents in TNBC (NCT03742349). The gene discussed is IL1B; the disease is neoplasm.